Evidence map›Paper›PMID 34135073›Full record

ArticleInternational journal of gynecological cancer : official journal of the International Gynecological Cancer Society2021

Impact of a tiered discharge opioid algorithm on prescriptions and patient-reported outcomes after open gynecologic surgery.

Sarah Huepenbecker, Robert Tyler Hillman, Maria D Iniesta, Tsun Chen, Katherine Cain, Gabriel Mena, Javier Lasala, Xin Shelley Wang, Loretta Williams, Jolyn S Taylor and 3 more

Open access · greenAbstract read
In one paragraph

Article in International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.0field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 7 citations in OpenAlex.

  1. Trial
  2. Evaluation of a tiered opioid prescription algorithm in an ERAS pathway: exploring opportunities for further refinement.International journal of gynecological cancer : official journal of the International Gynecological Cancer Society · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 1 country.

Sarah HuepenbeckerGynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.ORCID 0000-0003-3566-7393
Robert Tyler HillmanGynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.ORCID 0000-0002-9832-9925
Maria D IniestaGynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Tsun ChenSymptom Research, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Katherine CainDivision of Pharmacy, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Gabriel MenaAnesthesiology and Perioperative Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Javier LasalaAnesthesiology and Perioperative Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Xin Shelley WangSymptom Research, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Loretta WilliamsSymptom Research, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Jolyn S TaylorGynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Karen H LuGynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Pedro T RamirezGynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Larissa A MeyerGynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA lmeyer@mdanderson.org.ORCID 0000-0002-2687-7463
Gynecologic Oncology Group · USThe University of Texas MD Anderson Cancer Center · US

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8M
Training of Academic Gynecologic OncologistsT32CA101642 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI ANIL K SOOD, Kathleen Schmeler · 2005 to 2026
$9.2M
U.T. M. D. Anderson Cancer Center SPORE in Ovarian CancerP50CA217685 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI SOOD, ANIL K · 2017 to 2021
$7.9M
Improving Recovery after Major Cancer Surgery using Patient-Reported OutcomesR01CA205146 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI WANG, XIN SHELLEY · 2016 to 2019
$2.6M
Health Services Career Development: Improving Medical Decisions in Ovarian CancerK07CA201013 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI MEYER, LARISSA ALEJANDRA · 2016 to 2020
$853k
NCI NIH HHS K07 CA201013NCI NIH HHS P30 CA016672NCI NIH HHS P50 CA217685NCI NIH HHS R01 CA205146NCI NIH HHS T32 CA101642
6 · The paper itself

Abstract

objectiveTo compare discharge opioid refills, prescribed morphine equivalent dose and quantity, and longitudinal patient-reported outcomes before and after implementation of a tiered opioid prescribing algorithm among women undergoing open gynecologic surgery within an enhanced recovery after surgery program.

methodsWe compared opioid prescriptions, clinical outcomes, and patient-reported outcomes among 273 women. Post-discharge symptom burden was collected up to 42 days after discharge using the validated 27-item MD Anderson Symptom Inventory and analyzed using linear mixed effects models and Kaplan-Meier curves for symptom recovery.

resultsAmong 113 pre-implementation and 160 post-implementation patients there was no difference in opioid refills (9.7% vs 11.3%, p=0.84). The post-implementation cohort had a significant reduction in median morphine equivalent dose (112.5 mg vs 225 mg, p<0.01), with no difference in median hospital length of stay (3 days vs 3 days, p=1.0) or 30-day readmission rate (9.4% vs 7.1%, p=0.66). There was no difference in patient-reported pain between the pre- and post-implementation cohorts on the day of discharge (severity 4.93 vs 5.14, p=0.53) or in any patient-reported symptoms, interference measures, or composite scores by post-discharge day 7. The median recovery time for most symptoms was 7 days, except for pain (14 days), fatigue (18 days), and physical interference (21 days), with no differences between cohorts.

conclusionsAfter implementation of a tiered opioid prescribing algorithm, the quantity and dose of discharge opioids prescribed decreased with no change in post-operative refills and without negatively impacting patient-reported symptom burden or interference, which can be used to educate and reassure patients and providers.

Indexed as

AdultAgedAged, 80 and overAlgorithmsAnalgesics, OpioidFemaleGynecologic Surgical ProceduresHumansMiddle AgedPatient DischargePatient Reported Outcome MeasuresPostoperative PainProspective StudiesTreatment OutcomeAnalgesics, Opioidgynecologic surgical proceduresopioid-related disorderspostoperative care

Identifiers

PMID34135073
PMCPMC8328052
OpenAlexW3172925739

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.